STING1 and COVID-19: It has been demonstrated that STING agonists, such as diABZI, have potent antiviral activity against the respiratory RNA viruses human parainfluenza type 3 virus, rotavirus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, dependent on the IFN pathway (Zhu et al., 2020; Zhu et al., 2021).